US FDA Approves Less Frequent Lebrikizumab Dosing in AD The Dermatology Digest Source link
TDM-180935 is a small-molecule drug candidate intended to treat atopic dermatitis. Credit: Kaspars Grinvalds / Shutterstock. Chinese biopharmaceutical company Technoderma Medicines has begun dosing patients in its Phase IIa clinical trial of topical TDM-180935 ointment, a potential treatment for atopic dermatitis (AD). The eight-week trial will assess the two different strengths of the topical medication […]